The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
A legfontosabb adatok
- Ki végzi
- Boehringer Ingelheim
- Hol
- Kaohsiung City, Taichung, Taipei, Taoyuan és Yunlin County (Tajvan)Mind a 6 helyszín megnézéseMég 45 másik országban, 465 helyszínen
- Azonosító
- NCT06872892
- EU 2024-518589-29-00
- U1111-1317-2315
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 1755 fő, tervezett
- Kezdés
- 2025. jún. 9.
- Várható befejezés
- 2027. dec. 20.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- BI 1291583
- Placebo matching BI 1291583
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 12 or older with bronchiectasis, a lung disease with widened airways, who have had flare-ups that needed antibiotics.
- Életkor
- 12 years or older. Adolescents must weigh at least 35 kg (77 lb) at Visit 1.
- Nem
- All sexes can join.
- A betegség stádiuma
- Bronchiectasis seen on a CT scan and confirmed by a radiologist. Past scans must not be older than five years. In the 12 months before Visit 1, at least 2 flare-ups needing antibiotics. Or at least 1 flare-up plus an SGRQ Symptoms score of >40 (adults only), or high symptom burden in the doctor's view (adolescents only). Adults must be able to cough up sputum for a Pseudomonas aeruginosa test.
- Korábbi kezelés
- People must not have had a dipeptidyl peptidase-1 (DPP1) (Cathepsin C (CatC)) inhibitor before. People who only got placebo in such studies can join. People on long-term antibiotics or CFTR-MT must have had at least one flare-up since starting it.
A részvétel fő kizáró okai
- New immune system weakness (immunodeficiency) diagnosed within 1 year before randomisation
- Allergic bronchopulmonary aspergillosis, tuberculosis or non-tuberculosis mycobacterial infection that is being treated or needs treatment
- Cancer now or within 5 years before screening, except some treated in situ skin or cervix cancers
- Moderate or severe liver disease (Child-Pugh B or C), or eGFR <30 mL/min at Visit 1
- Major surgery within 6 weeks before randomisation or planned during the trial
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female participants. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1 % per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the participant information
- Signed and dated written informed consent and assent, if applicable, prior to admission to the study, in accordance with GCP and local legislation
- Age of participants when signing the informed consent/assent ≥12 years; -- Adolescents need to weigh at least 35 kg at Visit 1
- Clinical history consistent with bronchiectasis (e.g. cough, chronic sputum production, recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by CT scan where bronchiectasis has been documented by a radiologist; Participants whose past CT scan image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than five years
- Adult participants should be able to produce sputum for Pseudomonas aeruginosa assessment during the screening period
- History of documented pulmonary exacerbations (assessed and recorded by the investigator) requiring antibiotic treatment. In the 12 months before Visit 1, participants must have had either:; at least 2 exacerbations, or; at least 1 exacerbation and an St. George's Respiratory Questionnaire (SGRQ) Symptoms score of >40 at screening Visit 1 (adults only); at least 1 exacerbation and high symptom burden according to the investigator's judgement (adolescents only) For participants on oral or inhaled antibiotics as chronic treatment for bronchiectasis and participants on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT), at least one exacerbation must have occurred since initiation of antibiotics or CFTR-MT
Ki nem vehet részt
- Any clinically relevant (at the discretion of the investigator) acute respiratory infection or ongoing pulmonary exacerbation at screening visit or during the screening unless recovered in the opinion of the investigator prior to Visit 2
- Major surgery (major according to the investigator's assessment) performed within 6 weeks prior to randomisation or scheduled during trial period
- Previous treatment with a dipeptidyl peptidase-1 (DPP1) (Cathepsin C (CatC)) inhibitor. (Note: Participants that were randomised and only received placebo in studies with DPP1 (CatC) inhibitor are allowed.) Further exclusion criteria apply
- Any new or newly diagnosed condition of primary or secondary immunodeficiency within 1 year before randomisation
- Allergic bronchopulmonary aspergillosis being treated or requiring treatment
- Tuberculosis or non-tuberculosis mycobacterial infection being treated or requiring treatment
- Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated in situ non-melanoma skin cancers or in situ carcinoma of uterine cervix
- Evidence or medical history of moderate or severe liver disease (Child-Pugh score B or C hepatic impairment)
- Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the participant at risk by participating in the trial
- estimated Glomerular Filtration Rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) or Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) <30 mL/min at Visit 1
Helyszínek itt: Tajvan
Még 45 másik országban, 465 helyszínen
- Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TajvanContact: Boehringer IngelheimRésztvevőt keres
- Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TajvanContact: Boehringer IngelheimRésztvevőt keres
- Taichung Veterans General HospitalTaichung, TajvanContact: Boehringer IngelheimRésztvevőt keres
- National Taiwan University HospitalTaipei, TajvanContact: Boehringer IngelheimRésztvevőt keres
- Chang Gung Memorial Hospital, LinkouTaoyuan, TajvanContact: Boehringer IngelheimRésztvevőt keres
- National Taiwan University Hospital Yun-Lin BranchYunlin County, TajvanContact: Boehringer IngelheimRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
A teljes eredeti leírásKevesebb
The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months.
Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.
A vizsgálat 2 csoportja
- Treatment armA vizsgált kezelés
Kezelés: BI 1291583
- Placebo armPlacebo, összehasonlításként
Kezelés: Placebo matching BI 1291583
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY™ Study)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.ERJ open research, 2026
- A regiszteradat frissítve
- 2026. november 12.